Arax Advisory Partners’s iBio IBIO Stock Holding History

Arax Advisory Partners’s Portfolio IBIO Stock Details IBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-91	Closed	-$112	–	4050
2025 Q4	$112	Hold	91	–	–	﹤0.01%	3808
2025 Q3	$76	Hold	91	–	–	﹤0.01%	3515
2025 Q2	$70	Hold	91	–	–	﹤0.01%	2993
2025 Q1	$366	Sell	91 -1	-1%	-$4	﹤0.01%	2559
2024 Q4	$226	Buy	92 +91	+9,100%	+$234	﹤0.01%	2384
2024 Q3	$3	Hold	1	–	–	﹤0.01%	2612
2024 Q2	$3	Hold	1	–	–	﹤0.01%	2538
2024 Q1	$5	Hold	1	–	–	﹤0.01%	1311
2023 Q4	$2	Sell	1 -1	-50%	-$4	﹤0.01%	1332
2023 Q3	$11	Hold	2	–	–	﹤0.01%	1315
2023 Q2	$22	Hold	2	–	–	﹤0.01%	1264
2023 Q1	$75	Hold	2	–	–	﹤0.01%	1256
2022 Q4	$16	Buy	+2	New	+$68	﹤0.01%	1267
2021 Q4	–	Sell	-2	Closed	-$1K	–	1161
2021 Q3	$1K	Hold	2	–	–	﹤0.01%	914
2021 Q2	$1K	Buy	+2	New	+$1.46K	﹤0.01%	884
2020 Q4	$1K	Hold	2	–	–	﹤0.01%	700
2020 Q3	$2K	Hold	2	–	–	﹤0.01%	645
2020 Q2	$2K	Hold	2	–	–	﹤0.01%	635
2020 Q1	$1K	Buy	+2	New	+$770	﹤0.01%	648

Other funds holding IBIO

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Arax Advisory Partners's IBIO Position: Q1 2026 in Review

Arax Advisory Partners sold out of iBio (IBIO) in Q1 2026, closing a stake of 91 shares — an estimated $112 sold.

Arax Advisory Partners first reported a position in IBIO in Q1 2020 and held it in 19 quarters. The position peaked at $2K in Q3 2020. 52 funds tracked by Wall St. Rank hold IBIO as of Q1 2026.

Arax Advisory Partners reported no remaining iBio position as of Q1 2026 after selling out during the quarter.
Arax Advisory Partners sold 91 iBio shares in Q1 2026, an estimated $112.
Arax Advisory Partners first reported a position in iBio in Q1 2020 and held it in 19 quarters.
Arax Advisory Partners's iBio position peaked at $2K in Q3 2020.
52 funds tracked by Wall St. Rank held iBio as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.